
a) OB Subcommittee Updates shared: see posted slides for more information
i) 2 new OB measures have been released to the ‘All Measures’ and ‘Obstetric’ Dashboards
(1) TEMP 05-OB
(2) GA 02-OB
b) Cardiac Subcommittee Updates shared: see posted slides for more information
i) Seeking perfusionists who would like to join the subcommittee to provide input for the new
on-bypass hyperthermia avoidance measure. Please contact ajanda@med.umich.edu if
interested!
6) Measure Updates and Feedback
a) PAIN 01 and 02 (use of non-opioid adjuncts) attribution (Zoom recording discussion 1017-1020)
i) Several sites wish to include measure performance as part of provider emails
ii) Inaccurate to assign attribution related to a specific time period (induction, emergence) due
to variation in administration of adjuncts
iii) Decision: Assign attribution to all provider s providing care
iv) Will not affect sites who wish to view this measure at an institutional level only
b) Measure Review- NMB 02 (Dr. Tim Dubovoy, Michigan Medicine)
i) Feedback from Measure Reviewer
ii) Zoom Recording available to hear full discussion (Zoom recording discussion 1020-1048)
iii) Recommendation from reviewer to continue measure with modifications:
(1) Remove cardiac exclusion: per cardiac subcommittee
(2) Remove 3 hour period of no NMB as marker of success
(3) Remove 2 hour period of no NMB as marker of success: per Pediatric Subcommittee
(4) Remove defasciculating dose exclusion
(5) Modify last sentence of rationale to read:
(a) “Due to variability in duration of muscle relaxants, we recommend that
pharmacological reversal is administered when any non-depolarizing neuromuscular
blockers are administered unless full recovery is confirmed with a ratio of ≥0.9 by
quantitative monitoring.”
iv) Chat comments:
(1) Karen Domino (University of Washington): The ASA is currently working on a guideline re
measurement and reversal of neuromuscular blockade. Some local institutional policies
do not recommend reversal of NMB if the patient has already spontaneously recovered
measured by quantitative monitoring (≥0.9)
(2) Meridith Bailey (MPOG Coordinating Center): Peds Subcommittee reviewed this measure
last month and consensus among the group was to remove the 2 hour duration criteria
(3) Rob Schonberger (Yale): Hi all, this is Rob - regarding cardiac exclusion, I agree with prior
points. Have a manuscript under review presently showing more rapid cticu extubation
with protocolized reversal. So can we limit it if there is documented spontaneous
reversal?
(4) Tim Harwood (Wake Forest): 2-3 hours should cover ESRD patients
v) Vote:
(1) Continue as is (3/30: 10%)
(2) Modify (25/30: 83%)
(3) Retire (2/30:7%)
vi) Conclusion: